Cargando…
Exploring the effects of extracranial injections of botulinum toxin type A on prolonged intracranial meningeal nociceptors responses to cortical spreading depression in female rats
BACKGROUND: Botulinum neurotoxin type A, an FDA-approved prophylactic drug for chronic migraine, is thought to achieve its therapeutic effect through blocking activation of unmyelinated meningeal nociceptors and their downstream communications with myelinated nociceptors and potentially the vasculat...
Autores principales: | Melo-Carrillo, Agustin, Strassman, Andrew M, Schain, Aaron J, Noseda, Rodrigo, Ashina, Sait, Adams, Aubrey, Brin, Mitchell F, Burstein, Rami |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6779016/ https://www.ncbi.nlm.nih.gov/pubmed/31475573 http://dx.doi.org/10.1177/0333102419873675 |
Ejemplares similares
-
Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors’ responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle?
por: Zhang, XiChun, et al.
Publicado: (2016) -
Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains
por: Burstein, Rami, et al.
Publicado: (2014) -
OnabotulinumtoxinA affects cortical recovery period but not occurrence or propagation of cortical spreading depression in rats with compromised blood–brain barrier
por: Melo-Carrillo, Agustin, et al.
Publicado: (2021) -
Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons
por: Melo-Carrillo, Agustin, et al.
Publicado: (2020) -
Fluorescently-labeled fremanezumab is distributed to sensory and autonomic ganglia and the dura but not to the brain of rats with uncompromised blood brain barrier
por: Noseda, Rodrigo, et al.
Publicado: (2019)